By The Life Science Report

Source: Streetwise Reports   11/21/2018

A distributor of the proprietary product places a third large order.

Avivagen Inc. (VIV:TSX.V) announced in a news release it just sold 2 metric tons (2 mT) of OxC-beta Livestock to UNAHCO, the life sciences corporation’s exclusive distributor of the product in the Philippines.

“UNAHCO has reaffirmed its intention of making quarterly purchases of OxC-beta Livestock, which has become a growing and recurring revenue stream for Avivagen,” the release noted. The product now is registered in the Philippines for use in all animals that eat feed, primarily swine and broiler poultry. It is shown to be an effective, economic alternative to antibiotics commonly found in livestock feeds, the company noted.

With this order, UNAHCO has bought 7.2 metric tons so far this year and 9.1 metric tons since its first purchase in November 2016.

Avivagen noted that it continues to accelerate uptake of its OxC-beta Livestock product. Along with the Philippines, it is currently registered and available for purchase in Taiwan, Thailand and New Zealand.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

( Companies Mentioned: VIV:TSX.V,
)